Breast cancer - HER-2 + | ApexOnco - Clinical Trials news and analysis

x

“Top quality, fast and so easy to use”

Andrea Gnirke-Maier

Director New Product Planning

Morphosys

Click here for more information

Regulatory

5 June 2024

Jazz sets zani sights on a post-Enhertu world

Conferences Trial results

2 June 2024

ASCO 2024 – Enhertu nears its “ultralow” dream

But toxicity could hold back Destiny-Breast06's ability to change clinical practice.

Data insights Trial results

26 April 2024

Astra accelerates as Acerand enters the PARP1 race

Deals Trial results

31 August 2023

DualityBio and BioNTech take on Enhertu in HER2 low

Subscribe to Breast cancer - HER-2 +